Biotechs rush to disclose SVB exposure as industry grapples with bank failure’s fallout

As Silicon Valley Bank failed on Friday and went into federal receivership, more than 100 biotechs rushed to disclose their exposure and whether their cash balances would be affected.

For years, the bank has been a mainstay financial partner for biotech and tech startups, holding billions of dollars for...

Click to view original post